Latest Regulatory News

Unibail-Rodamco-Westfield N.V. reports a positive net income for the first half of 2025, driven by robust US shopping center performance and strategic investments. The company also advances its ESG commitments and plans to delist from the ASX by August.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Everest Metals Corporation has secured regulatory approval to begin mining at its Mt Dimer Taipan Gold & Silver Project, targeting production commencement in late 2025. The project’s inferred resource and ongoing contract negotiations position EMC for a promising small-scale operation.

TechGen Metals Ltd has announced a fully underwritten pro-rata non-renounceable entitlement issue to raise approximately $2.57 million, offering new shares at $0.018 each with free attaching options. The capital raise aims to accelerate exploration at key projects in Western Australia.

Lakes Blue Energy has extended the closing date of its Cleansing Prospectus Offer to November 5, 2025, aiming to smooth the path for secondary trading of new shares.

Domain Holdings Australia has confirmed a one-week delay in the implementation of its proposed CoStar scheme of arrangement, now set for 27 August 2025.

Leeuwin Metals Ltd has addressed a sudden spike in its share price and trading volume, confirming no undisclosed material information exists and attributing the movement to external market factors and a new research report.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

Shift4 Payments has secured Overseas Investment Office approval for its NZ$1.20 per share acquisition of Smartpay, advancing the proposed scheme of arrangement closer to completion.

Peel Mining Limited has updated its mineral resource estimates, highlighting a robust 22.9 million tonnes at 2.20% copper equivalent across its South Cobar Project. The company is advancing pre-feasibility studies and exploration drilling at key deposits, positioning itself as a significant player in the Cobar Basin copper hub.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.